Detalles de la búsqueda
1.
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Future Oncol
; 18(22): 2383-2392, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695563
2.
Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data.
Clin Epidemiol
; 15: 559-568, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37180565
3.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Crit Rev Oncol Hematol
; 190: 104089, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37562696
4.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nat Commun
; 14(1): 7018, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37919269
5.
Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors.
Clin Pharmacol Drug Dev
; 11(5): 585-596, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35157784
6.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol
; 40(28): 3246-3256, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35584336
7.
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nat Commun
; 14(1): 8223, 2023 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38086864
Resultados
1 -
7
de 7
1
Próxima >
>>